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INTRODUCTION
WHIM syndrome is a rare congenital immunodeficiency disease caused by aberrant activity of the chemokine CXCL12/CXCR4 axis (Hernandez et al., 2003; Bachelerie, 2010) . The disease is named after its main four clinical manifestations: Human Papilloma virus (HPV)-induced Warts, Hypogammaglobulinemia, recurrent bacterial Infections and Myelokathexis (Gorlin et al., 2000; Hernandez et al., 2003) . WHIM syndrome patients are generally panleukopenic and display a combination of WHIM syndrome-induced immunodeficiencies (Kawai and Malech, 2009; McDermott et al., 2011a) . In addition to a selective susceptibility to HPV-mediated pathogenesis (cutaneous and genital warts that cannot be controlled and might progress to cancer), patients are prone to recurrent bacterial infections and can develop various malignancies, including Epstein-Barr virus-associated lymphoproliferative diseases or primary cutaneous follicle center lymphoma (Imashuku et al., 2002; Chow et al., 2010; Beaussant Cohen et al., 2012; Yoshii et al., 2015; Meuris et al., 2016) . WHIM syndrome is primarily caused by heterozygous autosomal dominant CXCR4 mutations within the C-terminus of the receptor. Although the mutations are heterogeneous, they are all located in the region encoding for the carboxyl-terminus of the receptor, resulting into four nonsense and four frameshift truncation mutations (Beaussant Cohen et al., 2012; Al Ustwani et al., 2014; Liu et al., 2016) and one single point substitution (E343K) mutation (Liu et al., 2012) .
The most common WHIM variants are the R334X and S338X truncation mutants, which lack either 19 or 15 residues from the C-terminus (Table I) (McDermott et al., 2011b; Ballester et al., 2016) . These WHIM mutations render CXCR4 hyperresponsive to its ligand CXCL12 together with impaired desensitization and internalization of the mutant receptor (Balabanian et al., 2005) . Interestingly, besides the germline CXCR4 mutations in the WHIM syndrome, somatic WHIM-like mutations are found in 30% of the patients with Waldenström's macroglobulinemia, which have been correlated to tumor progression and drug resistance (Hunter et al., 2014; Roccaro et al., 2014; Kapoor et al., 2015) . Interestingly, distinct genetic mechanisms (e.g. germline vs. somatic) are associated with identical or highly similar mutations in the CXCR4 C-terminal region (Liu et al., 2016) . CXCR4 is widely expressed on leukocytes (Forster et al., JPET #242735 1999) , CXCR4 mutations also affect immunological processes and result in decreased levels of circulating leukocytes and immunoglobulins (Bock et al., 2014; Brault et al., 2014) . Considering the broad functions of CXCR4 in maintaining leukocyte homeostasis, patients suffering from the WHIM syndrome display altered immune responses likely as a consequence of impairment in the differentiation and trafficking of leukocytes (McDermott et al., 2015; Biajoux et al., 2016; Freitas et al., 2017) .
Currently, WHIM syndrome treatment consists of symptom relief, which does not target the aberrant CXCR4 signaling and are moderately effective. Treatments range from granulocyte colonystimulating factor to induce the release of immune cells from the bone marrow to prophylactic antibiotics against respiratory bacterial infections and intravenously administered immunoglobulins to compensate the hypogammaglobulinemia (Kawai and Malech, 2009 ). However, phase 1 clinical studies with the low molecular weight CXCR4 antagonist AMD3100 (plerixafor, Mobozil ® ) have demonstrated the potential of targeting CXCR4 in WHIM syndrome therapy (Dale et al., 2011; McDermott et al., 2011a; McDermott et al., 2014a) . AMD3100 is an FDA-approved drug for stem-cell mobilisation in non-Hodgkin's lymphoma and multiple myeloma. In addition, AMD3100 treatment effectively corrected panleukopenia (McDermott et al., 2011a) , decreased the disease burden and was relatively safe for relatively long term (6 months) and low dose use in WHIM patients (McDermott et al., 2014a) . However, in a different setting, single-dose or short term AMD3100 treatment was also associated with side effects such as: abdominal bloating, diarrhea, headache, nausea, lightheadedness, facial paresthesias and injection-site erythema (Liles et al., 2003; Devine et al., 2004) . Long term AMD3100 treatment for HIV-infections were discontinued due to potential cardiac toxicity (Scozzafava et al., 2002; De Clercq, 2003) . AMD3100 is also associated with suboptimal pharmacokinetic characteristics, such as a short in vivo half-life (3.5h) and limited oral bioavailability (Hendrix et al., 2000) . Altogether, this illustrates that treating WHIM syndrome by targeting CXCR4 might be effective but with the need to target it more safely.
The nanobody platform provides an alternative strategy to target CXCR4-WHIM signaling.
Nanobodies are 12-15 kDa recombinant single-domain antibody fragments and have advantages over small JPET #242735 6 molecule drugs in terms of target affinity and specificity. Another benefit of Nanobodies is their modular structure, which conveniently allows the generation of multivalent nanobody formats to improve functional affinity, increase in vivo half-life, bispecific targeting and/or allow tissue specific-targeting (Els Conrath et al., 2001; Mujic-Delic et al., 2014) . Because of their size and molecular structure, Nanobodies more readily recognize buried epitopes (e.g. GPCR ligand-binding pockets) as compared to conventional antibodies, have high protein stability and low immunogenicity (Steyaert and Kobilka, 2011; Mujic-Delic et al., 2014; Peyvandi et al., 2016 ). Previously, we described CXCR4-specific Nanobodies that antagonized CXCL12-dependent binding/signaling and inhibited HIV-infection (Jahnichen et al., 2010) . In this study, we evaluated the potential of CXCR4-targeting Nanobodies as WHIM syndrome therapeutics and compared their potencies in their ability to displace CXCL12 binding and inhibit CXCL12-induced signaling of both CXCR4-WT and -WHIM mutants.
JPET #242735 serum (FBS), 50 IU/ml penicillin and 50 μg/ml streptomycin (PAA Laboratories GmbH, Paschen, Austria).
Cells were grown at 37°C in a humidified atmosphere with 5% CO2 and passaged two times per week.
Transient transfections were performed using the polyethylenimine (PEI) method (Schlaeger and Christensen, 1999) .
I-CXCL12 displacement
Two million HEK293T cells were seeded in 10 cm cell culture dishes. After O/N cell growth the cells were transiently transfected with 250 ng hCXCR4-WT, hCXCR4-R334X or hCXCR4-S338X pcDEF3 supplemented to 5 μg using empty pcDEF3 vector. 48 hours post-transfection the CXCR4-expressing cell membranes were isolated as previously described (de Wit et al., 2016) . Radioligand displacement assays were performed as previously described (de Wit et al., 2016) . Briefly, in 96-well plates, approximately 75 pM 125 I-CXCL12 in HEPES Binding Buffer (50mM HEPES-HCl, pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 0.1 M NaCl, 0.5% (w/v) BSA) was added to increasing concentrations of unlabeled CXCL12, AMD3100, 10A10 or 10A10-10A10 Nanobodies. Radioligand only and radioligand + 100 nM CXCL12 were used as total binding and non-specific binding controls to each assay plate. The ligands were incubated with 5 μg/well CXCR4 (WT, R334X, S338X) or Mock HEK293T membranes for 2 hours at 20°C to reach binding equilibrium. The radioligand-bound membranes were harvested on 0.5% (w/v) PEI soaked GF/C filter plates (Perkin-Elmer) and dried for 30 minutes at 60°C. Scintillation fluid (MicroScint™-O, Perkin-Elmer) was added and radioactivity was measured using a MicroBeta liquid scintillation counter (Perkin-Elmer).
In addition to the radioligand competition plates, the fixed amount of radioligand is also directly added to a GF/C filter plate during each experiment, in order to determine the radioligand concentration in the displacement assay. The data was plotted and analyzed using a Competitive One-Site homologous binding fit for homologous displacement and Competitive One-Site FitLogIC50 binding fit for heterologous displacement with GraphPad Prism 6 software (GraphPad software Inc, San Diego, CA, USA).
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Immunofluorescence microscopy imaging
Transiently transfected (Mock or Fluor® 488-conjugated antibody (1:500 in blocking buffer) was applied for 1 hour at 20°C. Cell nuclei were stained using 4',6-diamidino-2-phenylindole (DAPI) (1 μg/ml) in PBS for 5 minutes at 20°C.
Immunofluorescence imaging was carried out using a Olympus FSX-100 microscope.
Cell surface radioligand binding
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SDS-PAGE and Western blotting
Transiently transfected (Mock, CXCR4-WT, CXCR4-R334X or CXCR4-S338X) HEK293T cells (3.10 5 ) cells were grown on a 12-well plate on full medium. Cells were synchronized by serum starvation with 0%
FBS DMEM and grown overnight. Synchronized cells were treated with CXCL12 (1 nM), AMD3100 (10 μM), 10A10 (1 μM) and/or 10A10-10A10 (100 nM). For CXCL12 inhibition experiments, the cells were pre-incubated for 1h at 37°C with the CXCR4-inhibitors prior to CXCL12 stimulation (1 nM). After 5 or 15 minutes of CXCL12 stimulation the cells were lysed on ice with RIPA buffer supplemented with 1 mM NaF, 1 mM NaVO4 and protease inhibitor cocktail (cOmplete, Roche), sonicated and centrifuged to remove insoluble cell debris. Protein content of the lysates was determined using a BCA protein estimation assay according to manufacturer's instructions (Thermo Fisher Scientific). Equal amounts of protein were resolved by SDS-PAGE analysis using 10% acrylamide gels. After electrophoresis, protein was to PVDF membranes (Bio-Rad), which was subsequently blocked for 1h at 22°C in 5% non-fat milk in 0. using Graphpad Prism version 6.0 (GraphPad Software, Inc., La Jolla, CA, USA). 
Intracellular calcium flux
Wound healing assay
Wound-healing assays were performed as described previously . In short, 1 × 10 5 HPV18 immortalized human keratinocytes were seeded on gelatin-fibronectin-coated coverslips and were grown to confluence in complete KSFM medium. Cells were scratched and incubated with or without Nanobodies or AMD3100 for 16 hours. Cells were fixed and subsequently stained for polymeric F actin and nuclei using TRITC-tagged phalloidin and Hoechst 33342, respectively. Scratch closure was then visualized by immunofluorescence microscopy. Size of the wound was automatically calculated using the Axiovision 4.6 software.
Data analyses
All data was obtained from at least three independent experiments in triplicates. All bar graphs and Fig. 1A) . Next, the effect of WHIM mutations on ligand-induced G protein signaling was assessed. Co-expression of the chimeric G-protein Gqi5 redirects CXCR4 signaling from the Gi pathway to Gq-mediated phospholipase C (PLC) activation, which can be readily quantified via inositol-phosphate (IP) accumulation (Conklin et al., 1993 Fig. 1B ), while no effect was observed on mock-transfected cells (Supplemental Figure 1A) . Moreover, at a similar expression level (Fig. 1C) a 2-fold increase in maximum response of CXCL12-induced IP accumulation was observed for the two CXCR4-WHIM receptors, as compared to CXCR4-WT. CXCL12 also results in CXCR4-mediated activation of the MAPK pathway. We therefore compared the CXCL12-induced ERK1/2 activation (phosphorylated at Thr202/Tyr204) by CXCR4-WT and WHIM mutant S338X (Fig. 1D) . Compared to the WT, CXCR4-S338X displayed a sustained increase in phosphorylation of Thr202/Tyr204 ERK1/2 levels upon CXL12 exposure. Taken together, although CXCL12 binding affinities and potencies are identical between WT and WHIM receptors, the degree of signaling of WHIM receptors is increased and prolonged.
As a novel approach to inhibit the hyperactivation of CXCR4-WHIM mutants, new CXCR4-targeting Nanobodies were selected of which nanobody 10A10 was selected as lead molecule. The Nanobodies were produced as monovalent nanobody and as bivalent nanobody-constructs in which two identical 10A10 Nanobodies were separated by a flexible glycine-serine (GGGGS)4 linker. These Nanobodies allowed a sensitive detection of cell surface and intracellularly localized CXCR4 in immunofluorescence microscopy, without any detectable background staining on mock or non-transfected cells ( Fig. 2A) . Both monovalent and bivalent Nanobodies and the reference compound AMD3100
This article has not been copyedited and formatted. The final version may differ from this version. displaced the radioligand (75 pM of 125 I-CXCL12) from CXCR4 in a dose-dependent manner (Fig. 2B) .
The Nanobodies displayed a high potency in displacing CXCL12 from CXCR4-WT (pIC50 values of 7.7 ± 0.2 for monovalent and 8.8 ±0.1 for bivalent), compared to AMD3100 (6.3 ± 0.1). The bivalent nanobody construct displayed a 10-fold increase in binding affinity, as compared to its monovalent variant, resulting in nanomolar binding affinity for CXCR4-WT. On the WHIM mutants, both monovalent and bivalent could displace CXCL12 binding (partial for the monovalent and full displacement for the bivalent nanobody. The affinities of the monovalent and bivalent Nanobodies for CXCR-WT and -R334X ( Fig. 2A, right) or -S338X (Supplemental Figure 1B) were comparable ( Table II) .
Human CXCR4 shares high sequence identity (90%) with its murine orthologue and binds the same endogenous chemokine (CXCL12) as the human receptor ACKR3 (31% sequence identity, also referred to as CXCR7) (Gravel et al., 2010) . Target-specificity was verified by 125 I-CXCL12 displacement assays on intact HEK293T cells transiently transfected with human CXCR4 (hCXCR4), human ACKR3 (hACKR3) or mouse CXCR4 (mCXCR4) (Fig. 2C) . While 10A10 fully displaced 125 I-CXCL12 from hCXCR4, it could not displace CXCL12 from ACKR3 or mCXCR4. This indicates that the nanobody 10A10 is specific for human CXCR4. Variations between human and murine CXCR4 orthologues are predominantly found in their extracellular loop 2 (ECL2) region (Fig. 2D) . For this reason, we subsequently assessed the binding of 10A10 to ECL2 point-mutants of hCXCR4 (D187V, F189V and V196E) (Fig. 2E) . These point mutations were previously shown to have no effect on cell surface expression and 12G5 antibody binding (Wang et al., 1998; Jahnichen et al., 2010) . While 10A10 showed high affinity binding to both CXCR4-WT (pKD value of 8.9 ± 0.06) and CXCR4-F189V (pKD value of 8.7 ± 0.03), a complete lack of binding was observed for the CXCR4-D187V mutant. This indicates an essential role for the acidic residue D187 in binding of 10A10 to CXCR4.
Following the evaluation of 10A10 binding characteristics, the CXCR4 Nanobodies were functionally characterized in CXCR4 signaling assays. The Nanobodies and AMD3100 fully antagonized CXCL12-induced signaling of CXCR4-WT and CXCR4-R334X (Fig. 3A) and CXCR4-S338X (Supplemental Figure 1C) mutants. However, the Nanobodies showed potencies that were up to 100 fold greater than that of AMD3100 (Table II) . We then evaluated the potential of the CXCR4 antagonists to inhibit CXCL12-induced, CXCR4-dependent ERK1/2 activation. Pre-incubation of CXCR4-WT or CXCR4-WHIM (R334X) expressing cells with saturating concentrations (>50x KD) of CXCR4 antagonist for a period of 1 hour, strongly inhibited the CXCL12-induced ERK1/2 activation after 5 or 15 minute treatments (Fig. 3B) . CXCR4-mediated signaling via Gαi results in reduced levels of cyclic-AMP (cAMP) associated with reduced CRE (cAMP response element) gene regulation. No differences in potency or efficacy in CXCL12-induced Gαi activation could be detected between WT and the WHIM mutants (Supplemental Figure 1D) . Inhibition of CXCL12-induced Gαi activation by either the Nanobodies or AMD3100 resulted in a dose-dependent increase in cAMP levels in case of either CXCR4-WT and CXCR4-R334X ( Fig. 3C-D) and CXCR4-S338X (Supplemental Figure 1E) . In case of CXCR4-WT, AMD3100
partially inhibited CXCL12-induced CRE-Luc activation, while the bivalent nanobody completely inhibited CXCL12-induced Gαi activation with increased potency (Table II) . None of the antagonists showed differences in potencies or efficacies between CXCR4-WT and the WHIM mutants.
After these initial pharmacological analyses in HEK293T cells, the CXCR4 Nanobodies were evaluated in more clinically relevant cell lines and assays. Previously, McDermott et al. generated CXCR4-WT and CXCR4-R334X overexpressing K652 cell lines, which are of myleoid leukemic origin (McDermott et al., 2011b) . Here, we used these cells to study real-time calcium flux responses upon CXCL12 stimulation. First, we analyzed the CXCL12 response in parental K562 cells or K562 cells expressing CXCR4-WT or CXCR4-R334X. The CXCR4-expressing cells clearly displayed an increase in intracellular calcium release upon CXCL12 stimulation, which was not detected in the parental K562 cells (Fig. 4A) . Moreover, this CXCL12-induced calcium response could be fully inhibited with either AMD3100 (10 μM) or 10A10-10A10 (100 nM) in case of CXCR4-WT and almost fully in case of the CXCR4-R334X mutant) ( Fig. 4B and Table II) .
WHIM syndrome has been linked to HPV-associated malignancies Beaussant Cohen et al., 2012) . Furthermore, HPV18-immortalized human keratinocytes (HK-HPV18) display autocrine CXCL12/CXCR4 signaling that enhances cell migration . We therefore assessed the effect of our CXCR4 Nanobodies on migration of these HK-HPV18 cells in a wound healing assay ( Fig. 4C-D) . Without treatment, this wound is closed entirely after 16 hours of culture. The bivalent Nanobodies significantly inhibited this would healing up to 60% in a dose-dependent manner (Fig. 4D) . In contrast, AMD3100 (25 μM) was only able to reach 26% of wound healing.
To summarize, these data indicate that the CXCR4 Nanobodies effectively antagonize CXCL12 function, with overall superior pharmacological characteristics as compared to AMD3100.
DISCUSSION
In this study, we pharmacologically characterized CXCR4-targeting Nanobodies on CXCR4-WT and WHIM-related CXCR4 mutants. Different WHIM mutants, predominantly varying in the length of their Cterminal tail, have been described that display similar biological phenotypes (Lagane et al., 2008; McCormick et al., 2009; McDermott et al., 2011b; Kallikourdis et al., 2013) . The most common WHIM mutants CXCR4-R334X and -S338X were taken along in our study (Beaussant Cohen et al., 2012) .
Homologous radioligand displacement showed similar binding affinities of CXCL12 for these WHIM mutants as to CXCR4 WT. Yet, WHIM mutants showed a two-fold increase in CXCL12-induced Gi response and phosphorylation of ERK1/2 activation was sustained. Furthermore, we observed no differences in cell surface expression, ligand binding and signaling between CXCR4-R334X and -S338X
receptors. These findings are in line with earlier reports that described increased and sustained signaling of CXCR4-WHIM mutants (Balabanian et al., 2005; Mueller et al., 2013; Cao et al., 2015) . CXCR4 is known to be ubiquitously expressed in several cell types, including HEK293T cells, which may complicate studying characteristics of CXCR4 mutants. In our signaling assays using HEK293T cells, we did not observe significant CXCL12 responses (Supplementary Figure 1A) in mock-transfected cells, indicating that the data generated with HEK293T-CXCR4 overexpression models was not compromised by endogenous CXCR4 expression.
In small scale WHIM syndrome clinical trials, the FDA approved small molecule CXCR4
antagonist AMD3100/plerixafor appeared relatively safe and effective for WHIM syndrome treatment. We characterized the ability of novel CXCR4-targeting Nanobodies, monovalent and bivalent 10A10, to inhibit the WHIM syndrome phenotype. In this study, AMD3100 was used as a benchmark antagonist of CXCL12-induced CXCR4 signaling. Radioligand displacement assays showed that the bivalent CXCR4-specific Nanobodies 10A10 fully inhibit binding of targeting Nanobodies are superior to AMD3100. The gain in potency observed for the bivalent nanobody is likely due to an increased binding avidity that is obtained by combining two binding affinities in one molecule (Rudnick and Adams, 2009; Vauquelin and Charlton, 2013) .
CXCR4 binds to its natural ligand CXCL12 via interactions with the N-terminus and ECL2 of the receptor (Brelot et al., 2000; Cutolo et al., 2017) . Within this ECL2, the aspartic acid at position 187 (D187)
was previously described to be involved in binding of CXCL12 (Brelot et al., 2000; Jahnichen et al., 2010; Wescott et al., 2016) . The D187 residue was also shown to be crucial for binding of the 10A10 CXCR4 nanobody to the receptor. In addition, mutation of the valine at position 196 (V196) caused a 10-fold decrease in affinity. The two previously described, chemokine-competing, CXCR4 Nanobodies 238D4 and 238D2 required either D187 (nanobody 238D4) or V196 (nanobody 238D2) (Jahnichen et al., 2010) . The overlap in ECL2 residues involved in binding of either CXCL12, the previously described Nanobodies and our new 10A10 nanobody correlates well with the ability of these Nanobodies to displace CXCL12 from CXCR4.
The potential of the CXCR4 Nanobodies to antagonize CXCL12-dependent signaling was evaluated in multiple functional assays that reflect divergent CXCR4 signaling routes or differences in the extent of signal amplification (2 nd messenger levels vs gene regulation). In general, each antagonist was equipotent and equieffective in antagonizing either CXCR4-WT or the CXCR4-WHIM receptors. The Nanobodies showed higher potencies in inhibiting CXCL12-induced Gi activation, as compared to AMD3100, with IC50 values that reflect their binding affinities. Also, in the cAMP reporter assay, the bivalent nanobody was significantly more potent than AMD3100. After these initial signaling studies in HEK293T cells, the Nanobodies were further validated in clinically more relevant, WHIM-related cell lines. In leukemic K562 cells, the CXCL12-induced calcium flux, mediated by either CXCR4-WT or CXCR4-R334X, was inhibited by both the Nanobodies and AMD3100. WHIM syndrome is often clinically characterized by HPV-associated warts and carcinogenesis. Such manifestations might be directly related to aberrant CXCR4-WHIM signaling, as suggested by the interplay between the CXCL12 signaling axis and the HPV life cycle Meuris et al., 2016) . Such interplay is notably manifested by the CXCL12-dependency of HPV-immortalized keratinocytes migration, which can be measured in a wound healing assay . We found that the nanobody dose-dependently inhibited the wound healing in HPV-immortalized keratinocytes up to 61%, whereas AMD3100 inhibited only 26% of the wound. Taken together, our functional experiments demonstrate that these new CXCR4 Nanobodies effectively inhibit CXCL12-dependent CXCR4 signaling with potencies that are superior of that of AMD3100.
Because of the small size and modular structure of Nanobodies, multivalent nanobody constructs are easily generated. Therefore, in order to extend the half-life of the Nanobodies in the blood circulation, target-specific Nanobodies are often coupled to Nanobodies directed against human-or murine albumin (Roovers et al., 2007; Tijink et al., 2008) . This half-life extension (HLE) can increase the half-life of the Nanobodies in blood up several days (Tijink et al., 2008) . For example, in clinical tests, IL6-receptor Nanobodies that have been modified accordingly, showed serum half-life of several weeks and therapeutic outcome upon weekly administration (Van Roy et al., 2015) . In contrast, AMD3100 is associated with poor pharmacokinetics (blood half-life of only a few hours) forcing its administration to WHIM patients twice a day (Hendrix et al., 2000; McDermott et al., 2014b) . Half-life extended variants of CXCR7-specific Nanobodies were described previously (Maussang et al., 2013) . Similar modification of the CXCR4 Nanobodies from this study would render them as potent alternatives for treatment of CXCR4-related diseases.
In recent years the nanobody platform has been gaining ground in GPCR-research as therapeutics, diagnostics and research tools (Mujic-Delic et al., 2014; Manglik et al., 2017) . Being stable proteins, Nanobodies can be readily tagged with fluorescent-probes, radiolabels or epitope-tags and thus utilized for CXCR4 detection, imaging and diagnostic purposes (e.g. ELISA, immunohistochemistry, immunofluorescence) or as crystallization chaperones (Mujic-Delic et al., 2014; Manglik et al., 2017) .
Being specific for human CXCR4 allows for detection of human CXCR4-expressing cells in human xenografts in animal experiments or detection of CXCR4 in immunohistochemistry on patient samples.
However, future testing of Nanobodies in an in vivo WHIM model, such as the Cxcr4 +/mutant(1013) model (the JPET #242735
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WHIM syndrome-associated CXCR4-S338X mutation) , would require mouse reactive Nanobodies. Furthermore, the extracellular localization of the binding epitope of these Nanobodies allows them to be used as targeting ligands in non-invasive imaging techniques, such as near-infra-red (NIR) or positron emission tomography (PET) imaging or for the delivery of therapeutic pay-loads to CXCR4-expressing cells (Oliveira et al., 2013) .
In conclusion, these data illustrate that the bivalent CXCR4-targeting nanobody 10A10-10A10 is highly potent in inhibiting CXCL12/CXCR4 signaling. Importantly, their modularity and HLE make these Nanobodies a promising alternative to AMD3100 for CXCR4-related diseases like WHIM syndrome and Waldenström's macroglobulinemia.
